Skip to main content
AI News List

List of AI News about AI drug discovery

Time Details
2026-01-21
03:00 UTC
Isomorphic Labs and J&J Innovation Partner to Accelerate AI Drug Discovery for Challenging Disease Targets

According to Isomorphic Labs (@IsomorphicLabs), the company has entered into a strategic partnership with Johnson & Johnson Innovation (@JNJInnovation) to leverage Isomorphic's AI drug design engine alongside J&J’s robust drug development capabilities. This collaboration aims to address historically difficult-to-drug disease targets by integrating cross-modality and multi-target research strategies. The partnership is expected to accelerate the path to new medicines and represents a significant advancement in digital biology, potentially unlocking novel molecules that traditional methods might overlook (source: @IsomorphicLabs, https://x.com/IsomorphicLabs/status/2013583586784387193).

Source
2026-01-01
05:30 UTC
5 Breakthrough AI Innovations in 2025 Revealed by Dr. Marc Siegel: Key Trends and Business Opportunities for 2026

According to Fox News AI on Twitter, Dr. Marc Siegel has highlighted five remarkable AI-driven advancements from 2025 that are shaping optimism for 2026. The article details how AI-enabled medical diagnostics, advanced robotics in healthcare, AI-assisted drug discovery, personalized mental health solutions, and next-generation AI-powered cybersecurity have demonstrated tangible impacts on both patient outcomes and operational efficiencies in the healthcare sector. These breakthroughs signal expanding market opportunities for AI startups and established enterprises to deliver transformative solutions across healthtech and cybersecurity. The report cites verified examples of AI reducing diagnostic errors and accelerating new drug development, suggesting that enterprises investing in these areas are poised for significant growth (source: Fox News AI, foxnews.com/opinion/dr-marc-siegel-5-incredible-miracles-from-2025-that-give-me-hope-2026).

Source
2025-12-09
08:07 UTC
Gigatime: Microsoft Scales Tumor Microenvironment Modeling with Multimodal AI for Breakthrough Oncology Research

According to Satya Nadella, Microsoft Research has introduced 'Gigatime', a cutting-edge platform that leverages multimodal AI to generate virtual populations for tumor microenvironment modeling. This advancement enables researchers to simulate complex biological interactions at scale, significantly accelerating oncology drug discovery and personalized medicine development. By integrating large-scale data and AI-driven insights, Gigatime addresses critical bottlenecks in preclinical cancer research, offering life sciences companies new tools to optimize treatment strategies and reduce R&D timelines (source: microsoft.com/en-us/research/blog/gigatime-scaling-tumor-microenvironment-modeling-using-virtual-population-generated-by-multimodal-ai/).

Source
2025-11-28
06:36 UTC
How John Jumper and AlphaFold 3 Revolutionize AI Protein Folding: Nobel-Winning Insights and Future Applications

According to Google DeepMind, John Jumper's journey from dropping out of his first PhD to earning a doctorate in AI and biology led to the development of AlphaFold, an AI model that has transformed protein folding prediction (source: @GoogleDeepMind). On the DeepMind podcast, Jumper discusses how AlphaFold 3 and diffusion models are accelerating scientific discovery, enabling breakthroughs in protein design and drug development. The episode highlights practical business opportunities, such as leveraging AI-driven protein engineering for pharmaceuticals and biotechnology innovation. The widespread adoption of AlphaFold demonstrates the commercial potential of AI in life sciences, with real-world use cases ranging from new medicine design to solving grand scientific challenges (source: @GoogleDeepMind, podcast episode Nov 28, 2025).

Source